Pfizer Ltd

Pfizer Ltd Share Price Today: Live Updates & Key Insights

Get insights on Pfizer Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Pfizer Ltd Share Price Chart

Pfizer Ltd Fundamentals

Traded Volume: 16,577

Market Cap(Cr): 22,876

Avg Traded Price 4988.09

1 Year return -2.55%

Upper Circuit 5,040

Lower Circuit 4,948

P/E TTM 27.00

P/B Ratio 183.00

Traded Value(Cr) 828.93

EPS TTM 183.465

Book value 183.465

Dividend 3.00%

Pfizer Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Pfizer Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Pfizer Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -0.85%

1M -6.09%

3M -11.58%

1Y -2.55%

YTD -5.26%

Pfizer Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Pfizer Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 6621.00

Day Before Yesterday 7960.00

1W Avg 7571.20

1M Avg 18682.10

3M Avg 24837.84

Pfizer Ltd Technical Details

Pfizer Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 4952

Support 2 4904

Support 3 4860

Pivot Point : 4996

Resistance 1 5044

Resistance 2 5088

Resistance 3 5136

Pfizer Ltd Corporate Actions

Pfizer Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Pfizer Ltd’s capital allocation strategies.

All

Ex-Date 09-Jul-2025 Type D Description 30.00/share@300.00% Record Date 09-Jul-2025 Ratio 300.00

Ex-Date 09-Jul-2025 Type D Description 100.00/share@1000.00% Record Date 09-Jul-2025 Ratio 1000.00

Ex-Date 09-Jul-2025 Type D Description 35.00/share@350.00% Record Date 09-Jul-2025 Ratio 350.00

Ex-Date 21-Aug-2024 Type D Description 35.00/share@350.00% Record Date 21-Aug-2024 Ratio 350.00

Ex-Date 11-Aug-2023 Type D Description 35.00/share@350.00% Record Date 11-Aug-2023 Ratio 350.00

Ex-Date 11-Aug-2023 Type D Description 5.00/share@50.00% Record Date 11-Aug-2023 Ratio 50.00

Ex-Date 19-Sep-2022 Type D Description 30.00/share@300.00% Record Date 20-Feb-2022 Ratio 300.00

Ex-Date 18-Aug-2022 Type D Description 35.00/share@350.00% Record Date 19-Aug-2022 Ratio 350.00

Ex-Date 11-Aug-2021 Type D Description 5.00/share@50.00% Record Date - Ratio 50.00

Ex-Date 11-Aug-2021 Type D Description 30.00/share@300.00% Record Date - Ratio 300.00

Ex-Date 27-Aug-2020 Type D Description 10.00/share@100.00% Record Date - Ratio 100.00

Ex-Date 06-May-2020 Type D Description 320.00/share@3200.00% Record Date 08-May-2020 Ratio 3200.00

Ex-Date 01-Aug-2019 Type D Description 22.50/share@225.00% Record Date - Ratio 225.00

Ex-Date 29-Aug-2018 Type D Description 20.00/share@200.00% Record Date - Ratio 200.00

Ex-Date 22-Aug-2017 Type D Description 5.00/share@50.00% Record Date - Ratio 50.00

Ex-Date 22-Aug-2017 Type D Description 15.00/share@150.00% Record Date - Ratio 150.00

Ex-Date 27-Jun-2016 Type D Description 15.00/share@150.00% Record Date - Ratio 150.00

Ex-Date 03-Jul-2015 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00

Ex-Date 05-Dec-2013 Type D Description 360.00/share@3600.00% Record Date 06-Dec-2013 Ratio 3600.00

Ex-Date 28-Aug-2013 Type D Description 20.00/share@200.00% Record Date - Ratio 200.00

Ex-Date 28-Aug-2013 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00

Ex-Date 24-Jul-2012 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00

Ex-Date 08-Jul-2011 Type D Description 4.00/share@40.00% Record Date - Ratio 40.00

Ex-Date 20-Jan-2011 Type D Description 12.50/share@125.00% Record Date 21-Jan-2011 Ratio 125.00

Ex-Date 15-Apr-2010 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00

Ex-Date 31-Mar-2009 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00

Ex-Date 03-Apr-2008 Type D Description 12.50/share@125.00% Record Date - Ratio 125.00

Ex-Date 03-Apr-2008 Type D Description 15.00/share@150.00% Record Date - Ratio 150.00

Ex-Date 09-Mar-2007 Type D Description 22.50/share@225.00% Record Date - Ratio 225.00

Dividends

Announcement Date 09-Jul-2025 Ex Dividend Date 09-Jul-2025 Dividend(%) 300

Announcement Date 09-Jul-2025 Ex Dividend Date 09-Jul-2025 Dividend(%) 1000

Announcement Date 09-Jul-2025 Ex Dividend Date 09-Jul-2025 Dividend(%) 350

Announcement Date 21-Aug-2024 Ex Dividend Date 21-Aug-2024 Dividend(%) 350

Announcement Date 11-Aug-2023 Ex Dividend Date 11-Aug-2023 Dividend(%) 350

Announcement Date 11-Aug-2023 Ex Dividend Date 11-Aug-2023 Dividend(%) 50

Announcement Date 19-Sep-2022 Ex Dividend Date 19-Sep-2022 Dividend(%) 300

Announcement Date 18-Aug-2022 Ex Dividend Date 18-Aug-2022 Dividend(%) 350

Announcement Date 11-Aug-2021 Ex Dividend Date 11-Aug-2021 Dividend(%) 50

Announcement Date 11-Aug-2021 Ex Dividend Date 11-Aug-2021 Dividend(%) 300

Announcement Date 27-Aug-2020 Ex Dividend Date 27-Aug-2020 Dividend(%) 100

Announcement Date 06-May-2020 Ex Dividend Date 06-May-2020 Dividend(%) 3200

Announcement Date 01-Aug-2019 Ex Dividend Date 01-Aug-2019 Dividend(%) 225

Announcement Date 29-Aug-2018 Ex Dividend Date 29-Aug-2018 Dividend(%) 200

Announcement Date 22-Aug-2017 Ex Dividend Date 22-Aug-2017 Dividend(%) 50

Announcement Date 22-Aug-2017 Ex Dividend Date 22-Aug-2017 Dividend(%) 150

Announcement Date 27-Jun-2016 Ex Dividend Date 27-Jun-2016 Dividend(%) 150

Announcement Date 03-Jul-2015 Ex Dividend Date 03-Jul-2015 Dividend(%) 125

Announcement Date 05-Dec-2013 Ex Dividend Date 05-Dec-2013 Dividend(%) 3600

Announcement Date 28-Aug-2013 Ex Dividend Date 28-Aug-2013 Dividend(%) 200

Announcement Date 28-Aug-2013 Ex Dividend Date 28-Aug-2013 Dividend(%) 125

Announcement Date 24-Jul-2012 Ex Dividend Date 24-Jul-2012 Dividend(%) 125

Announcement Date 08-Jul-2011 Ex Dividend Date 08-Jul-2011 Dividend(%) 40

Announcement Date 20-Jan-2011 Ex Dividend Date 20-Jan-2011 Dividend(%) 125

Announcement Date 15-Apr-2010 Ex Dividend Date 15-Apr-2010 Dividend(%) 125

Announcement Date 31-Mar-2009 Ex Dividend Date 31-Mar-2009 Dividend(%) 125

Announcement Date 03-Apr-2008 Ex Dividend Date 03-Apr-2008 Dividend(%) 125

Announcement Date 03-Apr-2008 Ex Dividend Date 03-Apr-2008 Dividend(%) 150

Announcement Date 09-Mar-2007 Ex Dividend Date 09-Mar-2007 Dividend(%) 225

Bonus

No Bonus has been declared by PFIZER

Splits

No Split has been declared by PFIZER

Others

Rights No Rights has been declared by PFIZER

Pfizer Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Pfizer Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Pfizer Ltd's relative performance and valuation against major competitors.

Stock Name Emcure Pharmaceuticals Ltd ₹1354.60 (-0.52%) M. Cap (Cr) 256.78 1 Yr Return (%) NaN% P/E (TTM) 32.38 PB Ratio 6.23

Stock Name Syngene International Ltd ₹629.25 (-0.84%) M. Cap (Cr) 253.55 1 Yr Return (%) -25.70% P/E (TTM) 54.15 PB Ratio 5.77

Stock Name Piramal Pharma Ltd ₹188.38 (-0.66%) M. Cap (Cr) 250.40 1 Yr Return (%) -23.39% P/E (TTM) -1054.76 PB Ratio 3.16

Stock Name Pfizer Ltd ₹5000.50 (-0.56%) M. Cap (Cr) 228.76 1 Yr Return (%) -2.55% P/E (TTM) 27.26 PB Ratio 5.42

Stock Name ERIS Lifesciences Ltd ₹1666.00 (-0.22%) M. Cap (Cr) 226.94 1 Yr Return (%) +21.88% P/E (TTM) 54.60 PB Ratio 8.19

Stock Name Cohance Lifesciences Ltd ₹589.30 (+1.28%) M. Cap (Cr) 225.45 1 Yr Return (%) -53.76% P/E (TTM) 90.96 PB Ratio 13.19

Stock Name Astrazeneca Pharma India Ltd ₹8988.00 (-1.59%) M. Cap (Cr) 224.70 1 Yr Return (%) +42.54% P/E (TTM) 112.83 PB Ratio 33.08

Pfizer Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Pfizer Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 659.75 Mar 2024 256.84 Mar 2023 355.68 Mar 2022 667.08 Mar 2021 427.33

PARTICULARS Investing Activities Mar 2025 -71.34 Mar 2024 53.70 Mar 2023 -36.05 Mar 2022 -575.02 Mar 2021 -468.84

PARTICULARS Financing Activities Mar 2025 -205.34 Mar 2024 -235.14 Mar 2023 -345.79 Mar 2022 -180.51 Mar 2021 -1571.07

PARTICULARS Net Cash Flow Mar 2025 383.07 Mar 2024 75.40 Mar 2023 -26.16 Mar 2022 -88.45 Mar 2021 -1612.58

Pfizer Ltd Shareholding Pattern

This shows the ownership breakdown of Pfizer Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 63.92%

Public 16.37%

Other Institutions 5.37%

FII 2.6%

Mutual Funds 11.74%

About Pfizer Ltd

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories. It has its own manufacturing facility at Goa and Thane. It has the distinction of being the first pharmaceutical company in India to start clinical research. The Company sells products in nearly 185 countries having 43 manufacturing sites globally. Their 6 primary therapeutic areas includes, Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Diseases.Pfizer Limited came to the Indian market on 21st November, 1950 through a company, 'Dumex Limited'. The first production facility was set up at Darukhanna in Mumbai, where products like Protinex and Isonex (isoniazid - an anti -TB drug) were manufactured. Subsequently, this plant also produced Becosules and Corex. In 1960, Pfizer established a large and modern plant at Thane, near Mumbai, which housed manufacturing, quality control and product research facilities. This plant won a number of national safety awards. In November of the year 1965, the Company had entered into a licence agreement with Pfizer Corporation continuing the royalty-free licence granted to it for the use of Pfizer processes, technical know-how, etc., relating to the manufacture of existing products in the pharmaceutical, veterinary and agricultural fields and giving the Company the right to obtain from Pfizer Corporation by Mutual agreement, technical know-how and other assistance relating to the manufacture of new items. A large research and development laboratory of the company at Thane was commissioned in the year 1969. As of 4th March of the year 1977, the company's status was changed as a public limited company. Piroxicam, a major anti-artharitic drug, was launched in India in the last quarter of the year 1989 under the brand name of DOLONEX. The former subsidiary Dumex Ltd was amalgamated with the company effect from 1st April of the year 1992 and also during the same year, the pharmaceuticals division introduced `Dolmex' intramuscular injection. Development Operations (Dev Ops) India, formerly a part of the Clinical Research Division, was established in 1995. The operations started with the hiring of a statistician in 1995. Pfizer had acquired the animal healthcare operations of SmithKline Beecham in the year 1996. The pace of work of Clinical Research Division was picked up in 1998 and this was followed by a substantial growth in terms of activities and resources, especially in data management. A dedicated Informatics group of the company for all technical and applications support has been available since 1997. The Company closed down its manufacturing plant at Ankleshwar with effect from 31st July of the year 1999. During the year 2000, PL made tie-up with Shantha Biotechnics for parallel marketing of its products. Express Pharma Biz Award came to company's hands in the year 2002 for overall performance. The operational merger between the company and Parke-Davis had been completed in the year 2002. A year after, in 2003, Pfizer had initiated the global implementation of 'Clinicopia Labelling and Clinicopia Supply Chain' a part of inferno's Clinical Trials management suite. In mid 2003, the Mumbai group was aligned under Dev Ops Europe to emphasize its focus on operations and facilitate more interactions and project engagements from all sites. In the year 2004, PL had entered into an agreement with Sanofi Synthelabo (India) Ltd for co-promotion of its product, Daxid. The Company's seven key brands (Corex, Becosules, Magnex, Dolonex, Gelusil, Minipress XL and Benadryl) had listed among the Top-100 Industry brands, in the year 2005. Viagra was the first global brand launched in December of the year 2005, followed by Caduet (a combination of atorvastatin and amlodipine for treatment of patients with dyslipidemia and hypertension) and LYRICA (pregabalin, for treatment of neuropathic pain), both of which launched in the first quarter of 2006. The Company bagged Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.The global divesture of the OTC business to Johnson & Johnson in December 2006 and Pfizer, won a US Supreme Court appeal in April of the year 2007 that aimed to open the company's Lipitor cholesterol pill, the most widely prescribed drug in the world, to generic competition, also in end of the year 2007, the company had transferred its exclusive license to Johnson & Johnson for a total consideration of Rs 2,148.51 million. Pfizer had launched Champix, a non-nicotine smoking cessation prescription drug during February of the year 2008.On 12 April 2009, Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, announced that it will make a tender offer to acquire a 33.77% stake in Pfizer Limited from public shareholders at a price of Rs. 675 per share. Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75% from the current level of 41.23%. The offer will represent a total value of up to Rs 680 crore, or approximately USD 136 million.The Board of Directors of Pfizer Ltd at its meeting held on 26 September 2009 approved the Scheme of Amalgamation of Duchem Laboratories Ltd (wholly owned subsidiary of Pfizer Ltd) and Pfizer Ltd. The Scheme is proposed to be effective 1 December 2008. The Transferor Company being the wholly owned subsidiary of Pfizer Ltd, no consideration shall be payable to the Transferor Company or its shareholders pursuant to the Amalgamation and the shares held by Pfizer Ltd and its nominees in the Transferor Company shall stand cancelled.The Board of Directors of Pfizer Ltd at its meeting held on 6 February 2012 approved the sale of its animal health division by way of a slump sale to its wholly owned subsidiary (being incorporated) in consideration of approximately Rs 440 crore, subject to adjustment for working capital, to be paid by the wholly owned subsidiary (being incorporated) either in cash and/or by issue of shares (at par or premium) on such terms as may be agreed to by the Board of Directors. In July 2011, Pfizer Inc USA., the Ultimate Holding Company of Pfizer Ltd, announced that it was reviewing strategic alternatives for its global animal health business. The Board of Directors of Pfizer Ltd at its meeting held on 8 November 2012 approved the sale of its animal health business to Pfizer Animal Health India Limited, a 100% indirect subsidiary of Pfizer Inc., USA for a consideration of Rs 471.60 crore.Pfizer Ltd issued to all concerned a lock out notice on 1 August 2014 at its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai (the Plant). This said notice for the proposed lock-out has been necessitated on account of several acts, as a result of which the Company is of the belief that it has become impossible for the management to continue with the operations of the Plant in a peaceful and productive manner. The above lock-out notice will have no impact on the business operations of the Company. The Company has in place a robust business continuity plan which will ensure that its medicines are available to the patients at all times.On 1 December 2014, Pfizer Limited announced the completion of the merger with Wyeth Limited. The Scheme of Amalgamation between Wyeth Limited and Pfizer Limited and their respective shareholders and creditors (Scheme) was sanctioned by the Bombay High Court vide its order dated 31 October 2014. As per the provisions of the Scheme, 7 (seven) equity shares of Rs. 10/- (Rupees Ten only) each fully paid up of Pfizer Limited, will be issued for every 10 (ten) equity shares of Rs.10/- (Rupees Ten only) each fully paid up held in Wyeth Limited. The merger places Pfizer Limited among the top 10 pharmaceutical companies in India by market share. Pfizer Inc., USA, through its subsidiaries holds the majority stake in both companies and will continue to remain the majority shareholder with an approximate 63.9% holding in Pfizer Limited, post-merger. Wyeth Ltd. is a market leader in vaccines and women's health. Wyeth has pioneered the introduction of several new therapies in India and was the first to launch hormone replacement therapy and conjugated pneumococcal vaccines for infants and adults.On 15 July 2015, Pfizer Ltd has informed the stock exchanges that the company has intimated the concerned authorities that it intends to effect closure of its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai ('the Plant') with effect from 16 September 2015. The decision to close the Plant is based on an assessment of its long term viability and its ability to achieve the needed production. There has practically been no production activity at this plant since 2013, and the closure will not impact the supply of any of the Company's medicines to patients.On 24 September 2015, Pfizer Ltd informed the stock exchanges that the company has intimated the concerned authorities that it has withdrawn its notice dated 15 July 2015, whereby it had intended to effect closure of its plant situated at Thane Belapur Road, K.U. Bazar P. O., Navi Mumbai ('the Plant'), as the Company has entered into a Business Transfer Agreement to sell the Plant as a going concern to Vidhi Research & Development LLP. On 23 September 2015, Pfizer Ltd had informed the stock exchanges that it had entered into a Business Transfer Agreement (BTA) for the transfer of the Company's business at the Thane Plant as a going concern to Vidhi Research and Development LLP in accordance with the terms of the agreement for a lump sum consideration of Rs 178 crore. On 14 March 2016, Pfizer Ltd. announced that it has discontinued the manufacture and sale of its drug 'Corex' with immediate effect in view of Government of India notification dated 10 March 2016 prohibiting the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect. The above prohibition is likely to have an adverse impact on the revenue and profitability of the company. The company is exploring all available options at its disposal. On the same day, the Delhi High Court granted an interim injunction suspending the operation of the said government notification banning the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup till the next date of hearing. Corex recorded sale of Rs 176 crore for the nine months period ended 31 December 2015. On 13 May 2016, Pfizer Ltd. announced that it has signed an agreement for the sale of four products marketed by its Global Established Products business in India. The brands Neko Soap, Sloans, Ferradol and Waterburys Compound will be divested to Piramal Enterprises Limited, for a consideration of Rs 110 crore, subject to adjustments for inventory on closing. The closure of this transaction is subject to obtaining requisite regulatory approvals and fulfilment of certain conditions by the parties.On 29 November 2016, Pfizer Ltd announced that has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg) as part of a comprehensive review of its respiratory offerings. The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year. The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex Cough Syrup formulation. Corex Cough Syrup recorded a sale of Rs 244.48 crores for the financial year ended 31 March 2016.On 18 January 2017, Pfizer Limited announced that it has entered into a Delegation of Authority (DoA) with AstraZeneca Pharma India Limited (AstraZeneca), pursuant to which AstraZeneca has granted certain authority to the company to conduct certain activities in India. The said DoA is a result of a global agreement whereby Pfizer Inc. through its affiliates acquired from AstraZeneca PLC (through its affiliates) the development and commercial rights of their late-stage small molecule anti-infectives business. By way of this DoA, the company has been granted the authority, inter alia, to carry out the activities of pricing and reimbursement negotiations, promotional, marketing, tendering, bidding, and distribution in relation the identified injectable antibiotic products. Pursuant to this, Meronem Injection which is currently marketed in India by AstraZeneca is expected to be transitioned to Pfizer Limited. On 31 May 2017, Pfizer Limited (India) informed the stock exchanges that it has entered into an agreement with AstraZeneca AB, Sweden, to acquire the brand 'Neksium' in India for a value of Rs 75 crore. The transaction is subject to completion of requisite clearances. Neksium was launched in India in the year 2006 and has developed strong equity with prescribers as a leading, high quality product in the Anti-Peptic Ulcerant space. Neksium, with the active ingredient Esomeprazole belongs to a class of pharmaceutical preparations called `Proton Pump Inhibitors' (PPI) which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the Acid Peptic Disorders (APD) spectrum. Neksium (esomeprazole) complements Pfizer Limited's existing product portfolio in the gastrointestinal (GI) therapeutic area.Pfizer Inc., USA had announced on October 10, 2017 that it was considering a review of strategic alternatives for its Global Consumer Healthcare business. Further to this, in December 2018, Pfizer Inc. had announced the formation of a joint venture between Pfizer Inc. and GlaxoSmithKline Plc. to create a premier global consumer healthcare company with robust iconic brands. The Company had been informed by Pfizer Inc. that the brands Anne French and Anacin which are currently marketed by your Company will become a part of the portfolio of the Joint Venture company. In 2019, Enbrel, the first Tumor Necrosis Factor (TNF) inhibitor was launched. It launched Zavicefta drug; in 2021, it launched Gastroesophageal Reflux Disease (GERD) Clinic.The Company on September 30, 2021 entered into a business transfer agreement (BTA) with Mylan Pharmaceuticals Private Limited (Mylan), subsidiary of Viatris Inc to transfer certain primarily off-patent branded and generic established medicines business comprising of six brands which included Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin along with related business assets and liabilities of Upjohn Business as a going concern to Mylan for a consideration of Rs 180.48 Crore. As a result, the Company transferred Upjohn business along with related business assets and liabilities to Mylan effective August 1, 2022.During the year 2022-23, the Company transferred its said Business Undertaking at Thane including the land, plant and machinery and all workmen employed to Vidhi Research & Development LLP effective February 24, 2023.In FY 2023-24, Company launched Betrecep (Tofacitinib) in July, 2023 for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Ulcerative Colitis. Becosules Syrup and Gelusil Raft preparation was launched in February, 2024.

Company Sec. & Compli. Officer

Prajeet Nair

Registered office The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E, Mumbai, Maharashtra, 400051

FAX :91-22-66932000

Background

Incorporation Year 1950

Face Value ₹10.00

Market Lot 1

Pfizer Ltd Latest News

VIEW MORE NEWS

FAQs on Pfizer Ltd